Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
BioStar Capital is a venture capital firm founded in 2005 by Dr. Louis A. Cannon, a recognized leader in cardiology. The firm is headquartered in Petoskey, Michigan, and specializes in transformative medical technologies. BioStar Capital operates five venture capital funds, managing a total of over $130 million in assets under management (AUM). The firm primarily invests in early- and late-stage companies within the cardiology, orthopedics, and robotics sectors, aiming to address unmet patient needs through innovative solutions.
Since its inception, BioStar Capital has established a strong track record, with nearly two-thirds of its investments resulting in successful exits. The firm’s unique structure integrates key opinion leader physicians into the General Partner model, providing clinical validation and strategic advisement to portfolio companies. This approach enhances the development and market entry of innovative medical technologies, making BioStar Capital a distinctive player in the venture capital landscape.
BioStar Capital's commitment to innovation in healthcare is reflected in its active participation in the venture capital ecosystem, including membership in the Michigan Venture Capital Association. The firm continues to seek investment opportunities that align with its mission of improving patient outcomes through advanced medical technologies.
BioStar Capital invests in innovative medical technologies that address unmet patient needs, with a particular emphasis on the cardiovascular and orthopedic sectors. The firm’s investment strategy includes 'smart' devices, robotics, minimally invasive solutions, cost-reduction technology, and outpatient-center technology. BioStar Capital targets investments across various stages, including seed, Series A, Series B, and growth equity, with initial investments typically ranging from $1 million to $10 million.
The firm prioritizes innovations that improve patient access and reduce costs, focusing on transformative medical technologies that benefit both patients and physicians. BioStar Capital’s physician-integrated General Partner model provides unique clinical validation and strategic advisement, allowing the firm to identify and support companies that are developing groundbreaking solutions in healthcare.
BioStar Capital's portfolio includes over 50 companies, showcasing a diverse range of innovative medical technologies. Notable companies in their portfolio include:
These companies represent BioStar Capital's commitment to advancing medical technology and improving patient outcomes through innovative solutions.
Dr. Louis A. Cannon - Founder, Senior Managing Director. Dr. Cannon is a recognized leader in cardiology and has extensive experience in medical technology investments.
Mark Toland - Managing Director. Toland brings a wealth of experience in venture capital and healthcare investments.
Ben Cannon - Growth Equity, Partner & Advisor. Ben Cannon focuses on growth equity investments and has a strong background in healthcare.
Dr. Alan Davis - Managing Director. Dr. Davis is an orthopedic surgeon with expertise in medical device development.
Steven Yakubov - Director. Yakubov has a background in healthcare investments and strategic advisement.
Steve Bonelli - CFO. Bonelli manages the financial operations of the firm.
William H. (Hank) Kucheman - Managing Director. Kucheman has extensive experience in venture capital and healthcare.
Jeremy Touroo - Director. Touroo focuses on investment opportunities in medical technology.
Sarah Petrowski - Executive Assistant. Petrowski supports the team with administrative functions.
To pitch to BioStar Capital, founders should send an email to info@biostarcapital.com. It is advisable to include a comprehensive pitch deck that outlines the business model, market opportunity, and technology. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
In December 2023, BioStar Capital successfully closed Fund V at $130.3 million, surpassing previous funds and demonstrating strong limited partner interest. This fund will continue to support investments in innovative medical technologies.
BioStar Capital has maintained an active presence in the venture capital landscape, consistently seeking investment opportunities in medical technology. The firm’s recent updates highlight its commitment to innovation in healthcare, although specific blog posts or publications were not noted.
What are BioStar Capital's investment criteria?
BioStar Capital focuses on innovative medical technologies that address unmet patient needs, particularly in the cardiovascular and orthopedic sectors. The firm invests in early- and late-stage companies, with a preference for 'smart' devices, robotics, and minimally invasive solutions.
How can startups apply or pitch to BioStar Capital?
Startups can reach out to BioStar Capital via email at info@biostarcapital.com. It is recommended to provide a detailed pitch deck outlining the business model, market opportunity, and technology.
What makes BioStar Capital different from other venture capital firms?
BioStar Capital integrates key opinion leader physicians into its General Partner model, providing unique clinical validation and strategic advisement to portfolio companies. This physician-integrated approach enhances the development and market entry of innovative medical technologies.
What is the geographic scope of BioStar Capital's investments?
BioStar Capital primarily invests in companies based in the United States, focusing on the healthcare, biotech, and robotics sectors.
What is the typical check size for investments?
BioStar Capital typically invests between $1 million and $10 million in its portfolio companies, depending on the stage and potential of the business.
What is BioStar Capital's post-investment involvement like?
BioStar Capital provides ongoing support to its portfolio companies through strategic advisement from its team of healthcare clinicians and financial professionals. This includes assistance with clinical validation, market entry strategies, and operational support.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.